December 18, 2020 -- Gyroscope Therapeutics has entered into a sponsored research agreement with the University of Pennsylvania (UPenn) and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases.
Together, CAROT and Gyroscope researchers will explore specific gene therapy targets for glaucoma, optic neuritis, and retinitis pigmentosa. Gyroscope has an exclusive option to the intellectual property derived from the research conducted under the agreement.
Gyroscope's lead investigational gene therapy is being evaluated in phase II clinical trials for the treatment of geographic atrophy secondary to dry age-related macular degeneration, a leading cause of blindness.
Financial details of the agreement were not disclosed.